Monsanto Company

Harvard College

Joseph Feder

William R Tolbert

Mau-Jung Kuo

Daniel T Connolly

Jitka V Olander

Jon P Schaumann

Richard C Kimes

Raymond A Dwek

Thomas William Rademacher

Arthur J Wittwer

Raj B Parekh

Mary M Hitt

Nicholaos K Harakas

Harold I Weingarten

Michael A Sanzo

Katharine Ku

Steven P Adams

Moses J Folkman

Susan C Howard

Charles Lewis, Jr

Margaret J Reents

Pamela J Keck

Mau-Jung Ku

Nicholaos K Hrakas

Medora M Hardy

Jayne C Marasa

A cDNA having a base sequence for human vascular permeability factor has been cloned and characterized and the amino acid sequence of the human vascular permeability factor protein has been determined.

DNA sequences encoding human vascular permeability factor having 189

A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics:

Tissue plasminogen activator inhibitor and method of purification

Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.

Large scale production of plasminogen activator from normal human colon

A method of producing antibodies against vascular permeability factor (VPF) is disclosed which comprises immunizing a host animal with a peptide having an amino acid sequence as follows: ##STR1## or a fragment of said peptide containing an antigenic determinant of VPF.

Antibodies to VPF

A method of stimulating endothelial cell growth is provided which comprises subjecting said cells to a growth stimulating amount of a highly purified vascular permeability factor having the following characteristics:

Stimulation of endothelial cell growth

A method is disclosed for increasing the yield of t-PA in culture of mammalian cells comprising introducing antibodies to the t-PA of said cells into the cell culture nutrient medium, allowing the cells to grow, and then recovering t-PA from the t-PA-antibody complex thus found in the conditioned medium by exchanging antibody in the complex for t-PA antibody immobilized on an inert support.

Method of increasing yield of t-PA in cell culture

Normal human colon fibroblast tissue plasminogen activator is separated by lysine-Sepharose affinity chromatography into Types I and II glycoforms and characterized with respect to the relative incidence of each type of oligosaccharide comprising the respective Types I and II glycoforms.

Tissue plasminogen activator from normal human colon cells

A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.

Monoclonal antibody specific for human colon fibroblast-derived t-PA

Monoclonal antibody specific for human colon fibroblast-derived T-PA

Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Tissue plasminogen activator oligosaccharide from normal human colon

The disclosure relates to novel synthetic thiopeptolide substrates having high activity for the enzyme collagenase. These substrates have the following amino acid sequences:

Novel thiopeptolide substrates for vertebrate collagenase

Thiopeptolide substrates for vertebrate collagenase

A method and apparatus for maintaining animal cells in vitro in a substantially arrested state of proliferation with continuous secretion of cell product is disclosed. The cells are retained within a reactor vessel chamber in a semi-rigid matrix having interstices for passage of fluid nutrient medium. Fresh nutrient medium is supplied by perfusion into the matrix through relatively low porosity tubes which are suspended in the reactor chamber and which substantially traverse the matrix; expended medium and cell product is withdrawn through relatively high porosity tubes which also are suspended in the reactor chamber and which substantially traverse the matrix; and oxygenated gaseous medium is supplied by perfusion into the matrix through a selectively-permeable membrane disposed in the reactor chamber.

Growing community of inventors

University City, MO, United States of America

Joseph Feder